StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Tyvyt (sintilimab) by Quarter

Tyvyt (sintilimab) — Worldwide revenue YoY (%) [legacy] (%)

QuarterlyAnnual

Eli Lilly Tyvyt (sintilimab): 30.0% in Q3 2024, down 20.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q3 2024
30.0%
Period ended Sep 30, 2024
Change on a year earlier
-20.0 pts
50.0% in Q3 2023
History
15 quarters
Since Q1 2021
Sources
15
Documents cited below

Where the Q3 2024 figure comes from

“|| Tyvyt ® | — | 150.2 | 150.2 | 115.1 | 30”

Source: Form 10-Q FY2024Q3 (filed 2024-10-30) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTyvyt (sintilimab) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q3 2024Sep 30, 202430.0%-20.0 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 202419.0%-22.0 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 202491.0%+120.0 ptsForm 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q4 2023Dec 31, 202398.0%+124.0 ptsEarnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 202350.0%+89.0 ptsEarnings Release (Form 8-K FY2023Q3 EX-99.1) (filed 2023-11-02) ↗
Q2 2023Jun 30, 202341.0%+71.0 ptsEarnings Release (Form 8-K FY2023Q2 EX-99.1) (filed 2023-08-08) ↗
Q1 2023Mar 31, 2023-29.0%-7.0 ptsEarnings Release (Form 8-K FY2023Q1 EX-99.1) (filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-26.0%-2.0 ptsEarnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022-39.0%-88.0 ptsForm 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-30.0%-94.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-22.0%-113.0 ptsForm 10-Q FY2022Q1 (filed 2022-04-29) ↗
Q4 2021Dec 31, 2021-24.0%–Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 202149.0%–Form 10-Q FY2021Q3 (filed 2021-10-27) ↗
Q2 2021Jun 30, 202164.0%–Form 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 202191.0%–Form 10-Q FY2021Q1 (filed 2021-04-30) ↗

Cite this data

StockData. (2026). Eli Lilly Tyvyt (sintilimab) (%), quarterly Q1 2021–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-tyvyt-yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.